Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services | News
Search Refinements

Contract Services News

View news from other Pharmaceutical sectors:
46-60 of 2369 results
Aralez acquires US rights to AstraZeneca high blood pressure drug Toprol-XL
By PBR Staff Writer
Aralez Pharmaceuticals Trading DAC (Aralez Ireland) has acquired the US rights to AstraZeneca’s generic high blood pressure drug Toprol-XL.
Contract Research & Services > Contract Services > News
Catalyst receives SPA from the FDA for second phase 3 trial assessing firdapse to treat LEMS
Catalyst Pharmaceuticals has reached an agreement with the US Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the protocol design, clinical endpoints, and statistical analysis approach to be taken in its upcoming Phase 3 study assessing Firdapse (amifampridine phosphate) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS).
Contract Research & Services > Contract Services > News
Dr Reddy's partners with Gland Pharma to market 8 ANDAs in US
Dr. Reddy’s Laboratories has partnered with Gland Pharma to market and distribute a diverse portfolio of eight injectable Abbreviated New Drug Applications (ANDAs).
Contract Research & Services > Contract Services > News
Zucara signs licensing deal with CDRD for therapeutic drug candidate
Zucara Therapeutics has signed a licensing agreement with the Centre for Drug Research and Development (CDRD) for access to a patented set of therapeutic drug compounds that will define its lead drug candidate.
Contract Research & Services > Contract Services > News
AstraZeneca to sell ex-US rights to Rhinocort Aqua nasal spray to J&J affiliate
By PBR Staff Writer
AstraZeneca has agreed to sell the rights outside the US for Rhinocort Aqua nasal spray to Johnson & Johnson’s affiliate Cilag GmbH International for $330m.
Contract Research & Services > Contract Services > News
Flamel Technologies signs deal with FDA on protocol for phase III trial of FT218
Flamel Technologies' Irish subsidiary, Flamel Ireland Holdings, has reached agreement with the US Food and Drug Administration (FDA) for the design and planned analysis of a Phase III clinical trial of FT218, a once nightly formulation of sodium oxybate utilizing the Company's proprietary drug delivery platform, Micropump.
Contract Research & Services > Contract Services > News
Insmed signs worldwide license deal with AstraZeneca for oral DPP1 inhibitor
Insmed has signed a licensing agreement with AstraZeneca for global exclusive rights to AZD7986, a novel oral inhibitor of dipeptidyl peptidase I (DPP1, also known as cathepsin C).
Contract Research & Services > Contract Services > News
Sarepta and Summit partner to develop novel therapies for Duchenne muscular dystrophy
Sarepta Therapeutics has entered into an exclusive licence agreement with Summit Therapeutics to develop drugs to treat Duchenne muscular dystrophy (DMD).
Contract Research & Services > Contract Services > News
Allergan signs $1.5bn licensing deal for AstraZeneca’s inflammatory diseases drug
By PBR Staff Writer
Allergan could pay as much as $1.52bn to MedImmune, the global biologics research and development arm of AstraZeneca, for the worldwide rights to an inflammatory diseases drug.
Contract Research & Services > Contract Services > News
Hanmi Pharmaceutical signs license deal with Genentech for novel Oral RAF inhibitor
Hanmi Pharmaceutical has entered into an exclusive development and license agreement with Genentech for the development and commercialization of its pan-RAF inhibitor, HM95573 which is currently in Phase I clinical development.
Contract Research & Services > Contract Services > News
ProNAi secures global rights to Chk1 inhibitor cancer drug candidate CCT245737
Sareum's co-investment partner, the CRT Pioneer Fund, has licensed exclusive and worldwide rights for the Chk1 inhibitor cancer drug candidate CCT245737 (to be renamed PNT737) to ProNAi Therapeutics.
Contract Research & Services > Contract Services > News
BioLineRx in-licenses novel treatment for liver failure conditions
BioLineRx has signed an exclusive, worldwide agreement with BGN Technologies, the Technology Transfer Company of Ben-Gurion University, and Hadasit, the Technology Transfer Company of Hadassah Medical Organization, for the in-licensing of a novel treatment for various liver failure conditions such as end-stage liver disease (ESLD) and for conditions potentially leading to liver failure such as non-alcoholic steatohepatitis (NASH).
Contract Research & Services > Contract Services > News
Ligand Pharmaceuticals licensing deals with Seelos Therapeutics for four programs
Ligand Pharmaceuticals has licensed rights to four programs to Seelos Therapeutics a newly formed biopharmaceutical firm focused on central nervous system (CNS), respiratory and other disorders.
Contract Research & Services > Contract Services > News
Midatech Pharma US partners with R-Pharm US to co-promote Zuplenz and Oravig
Midatech Pharma US has finalized a co-promotion agreement with R-Pharm US providing additional reach and frequency for the promotion of Zuplenz and Oravig to oncology accounts across the US.
Contract Research & Services > Contract Services > News
Dr. Reddy’s expands collaboration with Amgen in India
Dr. Reddy’s Laboratories has expanded its strategic collaboration with Amgen to market and distribute three of Amgen’s medicines in India in the therapy areas of oncology and osteoporosis.
Contract Research & Services > Contract Services > News
46-60 of 2369 results